Enara Bio announces the appointment of T-cell therapy leader Dr. Sophie Papa as Chief Medical Officer

Dr Sophie Papa

Enara Bio, the Oxford-based biotechnology company advancing novel T-cell receptor directed immunotherapies against unconventional, shared, cancer-specific antigens, has announced the appointment of Dr. Sophie Papa, FRCP, PhD as Chief Medical Officer.

Dr. Papa joins Enara Bio from King’s College London (KCL) and Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) where she was a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist. At both world-leading institutes, Dr. Papa led the delivery of cutting-edge first-in-human clinical trials in the cancer cell therapy space.

Kevin Pojasek, President and CEO of Enara Bio, commented: “I am delighted to welcome Sophie to Enara Bio as our Chief Medical Officer.

Her extensive experience spanning both preclinical and clinical research makes Sophie an ideal fit for our senior leadership team as we look towards advancing our ground-breaking science into the clinic. Sophie’s deep knowledge combined with her confident humility make her an exceptional addition as we continue to build Enara, based on a purpose-driven, self-led and inclusive culture.”

As a medical oncologist, Dr. Papa has broad expertise in the cancer immunotherapy space. She has been a frequent principal investigator as a member of the Guy’s and St Thomas’s Early Phase Trials Team, with a particular focus on the design and delivery of first-in-human studies of T-cell therapies for solid tumours.

As the program lead for cell therapy at GSTFT, Dr. Papa has expertise across the life cycle, from procurement to delivery, of complex cellular therapies. She also treated patients with malignant melanoma as a consultant in the skin cancer practice.

Dr. Papa added: “I am thrilled to join Enara Bio, a company exploring truly novel T-cell approaches to cancer immunotherapy outside the conventional areas of discovery.

“I have first-hand experience of the extraordinary impact of cancer immunotherapy advancements in recent years and with that, an understanding of the ongoing unmet clinical need. I look forward to working with the Enara team to bring the next generation of cancer cell therapies to the clinic, in what has become such an exciting therapeutic space.”

Dr. Papa completed her medical training at the University of Oxford and Imperial College London and went on to complete a PhD in solid tumour CAR T-cell cancer immunotherapy at King’s College London.

As a clinical academic, her research interest has been in the field of immune-oncology, particularly enhancing CAR-T cell clinical translation and understanding the role of the immune system in checkpoint inhibitor therapy.